Arcus Biosciences, Inc.

RCUS XNYS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

3.6B

Short interest (Jul 15)

10.0%

Net Short (Jul 27 ): 0.2%

Borrow Fee

0.28%

↑ 11.0%

Available Shares

↑ 20.0%

Price Chart

Company Overview

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Company Info

Exchange: NYSE

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001724521

Asset Type: CS

Market Data

Market Cap: $3,574,473,264

Employees: 601

Status: Active

Short Interest

Current Borrow Fee 0.28%

Range: 0.28% - 0.28%

Available Shares 1M

Range: 950K - 1M

Recent Changes

Fee Change: ↓ 0.0%

Available Change: ↓ 2.6%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime